Microbiome based therapeutics- reengineering strain of bacteria
Azitra is a preclinical company focused on microbiome-based therapeutics based on a unique technology developed at Yale. Azitra is developing a platform that consists of a safe, re- engineered strain of bacteria that is able to establish residence on human skin and secrete a therapeutic protein. Azitra addresses the high unmet need of a solution for eczema (or atopic dermatitis, AD), which affects approximately 10% children under the age of 13 and 1-2% of adults (11 million) in the US. The market for AD products is $1-2 billion dollars.
Azitra has raised $3.9 million in dilutive and non-dilutive funding so far.
Azim Munivar, Co-founder, CEO
Travis Whitfill MPH, Co-founder, CSO